Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?

Gilead Sciences Inc. (NASDAQ:GILD) is one of the top large cap value stocks to buy now. On June 8, Gilead Sciences and Merck announced positive topline results from two Phase 3 clinical trials, ISLEND-1 and ISLEND-2, evaluating their investigational once-weekly oral HIV treatment. The regimen, which combines islatravir and lenacapavir, successfully met its primary efficacy endpoint at Week 48 in both studies, showing statistical non-inferiority when compared to daily standard-of-care antiretroviral therapies.

This novel combination uses two distinct mechanisms of action: islatravir, a next-generation nucleoside analog, and lenacapavir, a first-in-class capsid inhibitor that disrupts the HIV lifecycle at multiple stages. The companies reported that the safety profile of the once-weekly tablet was generally comparable to existing treatments, with no new safety concerns identified throughout the trials.

If approved, the regimen would become the first long-acting oral HIV treatment taken only once per week, offering patients increased flexibility and discretion. Gilead Sciences Inc. (NASDAQ:GILD) and Merck plan to submit these Phase 3 findings to global regulatory authorities and present detailed data at an upcoming scientific congress to further support the development of this potential new standard of care.

Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.